Literature DB >> 21147548

Frequent hypermethylation of DAPK, RARbeta, MGMT, RASSF1A and FHIT in laryngeal squamous cell carcinomas and adjacent normal mucosa.

Jarosław Paluszczak1, Paulina Misiak, Małgorzata Wierzbicka, Aldona Woźniak, Wanda Baer-Dubowska.   

Abstract

Laryngeal cancers are the most frequent cancers of the head and neck region. While recent observations indicate the occurrence of an epigenetic field defect in head and neck cancer patients, a detailed exploration of the characteristic changes in the DNA methylation profile in laryngeal cancer patients was lacking. The aim of this study was to assess the methylation frequency of seven genes in a group of patients with primary laryngeal squamous cell carcinoma. Along tumor sections, matching samples of normal mucosa from epiglottis and trachea were analyzed. Gene methylation was assessed using the methylation-specific polymerase chain reaction. We found frequent gene hypermethylation in both the tumor and normal mucosa samples. The methylation of MGMT in tumor cells was associated with lymph node involvement. We report that laryngeal squamous cell carcinomas are characterized by frequent hypermethylation of DAPK, RARbeta, MGMT, RASSF1A and FHIT. Moreover, evidence is shown for the occurrence of a large epigenetically changed field of epithelial cells in laryngeal cancer patients. Our findings indicate the high prevalence of epigenetic abnormalities in laryngeal tumors.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21147548     DOI: 10.1016/j.oraloncology.2010.11.006

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  27 in total

1.  Environmental chemical exposures and human epigenetics.

Authors:  Lifang Hou; Xiao Zhang; Dong Wang; Andrea Baccarelli
Journal:  Int J Epidemiol       Date:  2011-12-13       Impact factor: 7.196

2.  The methylation of a panel of genes differentiates low-grade from high-grade gliomas.

Authors:  Aleksandra Majchrzak-Celińska; Jarosław Paluszczak; Marlena Szalata; Anna-Maria Barciszewska; Stanisław Nowak; Robert Kleszcz; Adam Sherba; Wanda Baer-Dubowska
Journal:  Tumour Biol       Date:  2015-01-08

3.  Expression of the tumor suppressor gene hypermethylated in cancer 1 in laryngeal carcinoma.

Authors:  Jarosław Markowski; Aleksander L Sieroń; Katarzyna Kasperczyk; Monika Ciupińska-Kajor; Aleksandra Auguściak-Duma; Wirginia Likus
Journal:  Oncol Lett       Date:  2015-02-25       Impact factor: 2.967

4.  [Promoter methylation and expression of death-associated protein kinase gene in acute leukemia].

Authors:  Wei-Hua Zhao; Fan-Yi Meng; Yong-Rong Lai; Zhi-Gang Peng; Jie Ma
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-03-20

Review 5.  Frequent chromosomal aberrations and candidate genes in head and neck squamous cell carcinoma.

Authors:  Krzysztof Szyfter; Malgorzata Wierzbicka; Jennifer L Hunt; Alessandra Rinaldo; Juan P Rodrigo; Robert P Takes; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-10-30       Impact factor: 2.503

6.  Methylation-mediated molecular dysregulation in clinical oral malignancy.

Authors:  Rebecca Towle; Cathie Garnis
Journal:  J Oncol       Date:  2012-05-07       Impact factor: 4.375

7.  Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells.

Authors:  Dimitrios Koutsimpelas; Warut Pongsapich; Ulf Heinrich; Sylvia Mann; Wolf J Mann; Jürgen Brieger
Journal:  Oncol Rep       Date:  2012-01-09       Impact factor: 3.906

8.  Association of Cigarette Smoking with Aberrant Methylation of the Tumor Suppressor Gene RARβ2 in Papillary Thyroid Cancer.

Authors:  Katja Kiseljak-Vassiliades; Mingzhao Xing
Journal:  Front Endocrinol (Lausanne)       Date:  2011-12-08       Impact factor: 5.555

9.  Comprehensive analysis of DNA methylation in head and neck squamous cell carcinoma indicates differences by survival and clinicopathologic characteristics.

Authors:  Justin A Colacino; Dana C Dolinoy; Sonia A Duffy; Maureen A Sartor; Douglas B Chepeha; Carol R Bradford; Jonathan B McHugh; Divya A Patel; Shama Virani; Heather M Walline; Emily Bellile; Jeffrey E Terrell; Jay A Stoerker; Jeremy M G Taylor; Thomas E Carey; Gregory T Wolf; Laura S Rozek
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

Review 10.  Epigenetically inactivated RASSF1A as a tumor biomarker.

Authors:  Dora Raos; Monika Ulamec; Ana Katusic Bojanac; Floriana Bulic-Jakus; Davor Jezek; Nino Sincic
Journal:  Bosn J Basic Med Sci       Date:  2021-08-01       Impact factor: 3.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.